Patricia Walker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Patricia Walker has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Ahmet Uluer
Department of Pediatrics Division of Pulmonary Medicine, Boston Children's Hospital Harvard Medical School Boston Massachusetts USA
1 shared publication - Amalia S. Magaret
University of Washington, Seattle, WA, United States
1 shared publication Amy Plachta
Lenox Hill Hospital Northwell Health, New York, NY, United States
1 shared publicationAndrea Roe
University of Pennsylvania
1 shared publication- Anna E. Fiastro
Department of Family Medicine, University of Washington, Seattle, Washington
1 shared publication - Anna M. Georgiopoulos
Massachusetts General Hospital, Boston, MA, USA
1 shared publication
Latest Publications
- 22 January 2025
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 24 (3) , 491-497
Contraceptive use and pregnancy in cystic fibrosis: Survey findings from 10 cystic fibrosis centers
- 22 January 2025
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 24 (3) , 491-497
Contraceptive use and pregnancy in cystic fibrosis: Survey findings from 10 cystic fibrosis centers
- 10 November 2023
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 23 (4) , 804-810
Palliative care needs among outpatient adults with cystic fibrosis: Baseline data from the Improving Life with CF trial
- 10 November 2023
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 23 (4) , 804-810
Palliative care needs among outpatient adults with cystic fibrosis: Baseline data from the Improving Life with CF trial
- 1 October 2014
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 134, 123
A Pooled Analysis of the Safety and Efficacy Results of the Multicenter, Double-Blind, Randomized, Placebo-Controlled Phase 3 REFINE-1 and REFINE-2 Trials of ATX-101, a Submental Contouring Injectable Drug for the Reduction of Submental Fat
- 1 October 2014
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 134, 123
A Pooled Analysis of the Safety and Efficacy Results of the Multicenter, Double-Blind, Randomized, Placebo-Controlled Phase 3 REFINE-1 and REFINE-2 Trials of ATX-101, a Submental Contouring Injectable Drug for the Reduction of Submental Fat
- Open Access
- 11 December 2003
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 149 (6) , 1259-1265
Optimizing the frequency of outpatient short-contact dithranol treatment used in combination with broadband ultraviolet B for psoriasis: a randomized, within-patient controlled trial
Background Recent concerns over the side‐effects of psoralen plus ultraviolet (UV) A, immunosuppressive and cytotoxic treatments have led to increased interest in dithranol for treatment of psoriasis. Few studies have investigated how frequently dithranol should be applied. Dithranol‐induced inflammation is maximal at 48–72 h, suggesting that daily application of dithranol may not be optimal. Objectives To investigate the effectiveness of five times weekly application of short‐contact dithranol (SCD) compared with three times weekly application in a dedicated hospital outpatient treatment unit. Methods A randomized, within‐patient, controlled study was performed. Patients had SCD applied five times weekly to one half of the body, and three times weekly to the other side. Whole‐body UVB irradiation was given 5 days a week. Patients were assessed weekly for 8 weeks. Principal outcome measures were percentage reduction in modified Psoriasis Area and Severity Index (mPASI) at the end of study and time to 50% improvement in mPASI score. Results Twenty‐nine patients were recruited; four were excluded from analysis. Mean percentage reduction in mPASI score at the end of study for five times weekly application was 57·3% (95% confidence interval, CI 39·6–75·0%) and for three times weekly application was 55·4% (95% CI 37·8–73·1%; P = 0·34). Mean time to 50% improvement in mPASI for five times weekly treatment was 4·1 weeks and for three times weekly treatment was 4·0 weeks (P = 0·50). There was no difference in the frequency or severity of burning episodes for each side. Conclusions This study suggests that three times weekly application of SCD may be as effective as five times weekly when used in conjunction with UVB administered five times weekly. Large studies of whole‐body comparisons are warranted to assess further the optimal frequency of SCD and UVB therapy for psoriasis.
- 11 December 2003
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 149 (6) , 1259-1265
Open AccessOptimizing the frequency of outpatient short-contact dithranol treatment used in combination with broadband ultraviolet B for psoriasis: a randomized, within-patient controlled trial
Background Recent concerns over the side‐effects of psoralen plus ultraviolet (UV) A, immunosuppressive and cytotoxic treatments have led to increased interest in dithranol for treatment of psoriasis. Few studies have investigated how frequently dithranol should be applied. Dithranol‐induced inflammation is maximal at 48–72 h, suggesting that daily application of dithranol may not be optimal. Objectives To investigate the effectiveness of five times weekly application of short‐contact dithranol (SCD) compared with three times weekly application in a dedicated hospital outpatient treatment unit. Methods A randomized, within‐patient, controlled study was performed. Patients had SCD applied five times weekly to one half of the body, and three times weekly to the other side. Whole‐body UVB irradiation was given 5 days a week. Patients were assessed weekly for 8 weeks. Principal outcome measures were percentage reduction in modified Psoriasis Area and Severity Index (mPASI) at the end of study and time to 50% improvement in mPASI score. Results Twenty‐nine patients were recruited; four were excluded from analysis. Mean percentage reduction in mPASI score at the end of study for five times weekly application was 57·3% (95% confidence interval, CI 39·6–75·0%) and for three times weekly application was 55·4% (95% CI 37·8–73·1%; P = 0·34). Mean time to 50% improvement in mPASI for five times weekly treatment was 4·1 weeks and for three times weekly treatment was 4·0 weeks (P = 0·50). There was no difference in the frequency or severity of burning episodes for each side. Conclusions This study suggests that three times weekly application of SCD may be as effective as five times weekly when used in conjunction with UVB administered five times weekly. Large studies of whole‐body comparisons are warranted to assess further the optimal frequency of SCD and UVB therapy for psoriasis.